Actress and singer Keke Palmer recently shared her experience navigating premenstrual dysphoric disorder (PMDD) at the 3rd annual Women's Health Lab in New York City, describing symptoms she found "unbearable" despite struggling to obtain a diagnosis.
PMDD is a severe form of premenstrual syndrome that affects roughly 5 to 8 percent of menstruating people. Unlike standard PMS, PMDD involves intense mood changes, depression, anxiety, and sometimes suicidal ideation that emerge one to two weeks before menstruation and resolve after bleeding begins. The condition qualifies as a mental health disorder in the Diagnostic and Statistical Manual of Mental Disorders.
Palmer's public discussion highlights a widespread diagnostic challenge many people face. PMDD remains underrecognized and underdiagnosed, partly because symptoms overlap with other mental health conditions and partly because healthcare providers lack sufficient training in recognizing the condition's cyclical pattern. Patients often receive misdiagnoses of bipolar disorder, depression, or anxiety disorders before someone finally identifies PMDD.
The delayed recognition delays treatment. PMDD responds well to targeted interventions, including selective serotonin reuptake inhibitors (SSRIs) taken continuously or just during the luteal phase, lifestyle modifications, cognitive behavioral therapy, and tracking symptom patterns across menstrual cycles.
Tracking menstrual symptoms for multiple cycles proves essential for diagnosis. Healthcare providers look for a consistent pattern of severe mood changes, fatigue, concentration problems, appetite changes, or physical symptoms tied specifically to the luteal phase. Many people benefit from symptom logs or cycle-tracking apps that help establish this timeline.
Palmer's willingness to speak publicly about her diagnostic journey may help normalize conversations around PMDD and encourage others to advocate for themselves within healthcare systems. Many people with PMDD report feeling dismissed or told their